HK1073851A1 - Human cdr-grafted antibodies and antibody fragments thereof - Google Patents

Human cdr-grafted antibodies and antibody fragments thereof

Info

Publication number
HK1073851A1
HK1073851A1 HK05106562.0A HK05106562A HK1073851A1 HK 1073851 A1 HK1073851 A1 HK 1073851A1 HK 05106562 A HK05106562 A HK 05106562A HK 1073851 A1 HK1073851 A1 HK 1073851A1
Authority
HK
Hong Kong
Prior art keywords
human cdr
antibody fragments
human
ccr4
antibody
Prior art date
Application number
HK05106562.0A
Other languages
English (en)
Inventor
Kenya Shitara
Kazuyasu Nakamura
Emi Hosaka
Akiko Tanaka
Masamichi Koike
Original Assignee
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kirin Co Ltd
Publication of HK1073851A1 publication Critical patent/HK1073851A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4719—G-proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7158—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for chemokines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
HK05106562.0A 2001-08-31 2005-08-01 Human cdr-grafted antibodies and antibody fragments thereof HK1073851A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001265144 2001-08-31
PCT/JP2002/008828 WO2003018635A1 (en) 2001-08-31 2002-08-30 Human cdr-grafted antibodies and antibody fragments thereof

Publications (1)

Publication Number Publication Date
HK1073851A1 true HK1073851A1 (en) 2005-10-21

Family

ID=19091652

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05106562.0A HK1073851A1 (en) 2001-08-31 2005-08-01 Human cdr-grafted antibodies and antibody fragments thereof

Country Status (23)

Country Link
US (8) US7504104B2 (ja)
EP (1) EP1449850B9 (ja)
JP (1) JP4052515B2 (ja)
KR (1) KR100959248B1 (ja)
CN (1) CN100430420C (ja)
AT (1) ATE490277T1 (ja)
AU (1) AU2002338015B8 (ja)
BE (1) BE2019C006I2 (ja)
BR (1) BRPI0212266B8 (ja)
CA (1) CA2458627C (ja)
CO (1) CO5560582A2 (ja)
CY (2) CY1111193T1 (ja)
DE (1) DE60238503D1 (ja)
DK (1) DK1449850T3 (ja)
ES (1) ES2356190T3 (ja)
FR (1) FR19C1028I2 (ja)
HK (1) HK1073851A1 (ja)
LU (1) LUC00116I2 (ja)
MX (1) MXPA04001894A (ja)
NL (1) NL300985I2 (ja)
NO (1) NO334858B1 (ja)
PT (1) PT1449850E (ja)
WO (1) WO2003018635A1 (ja)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2270150B2 (en) * 1999-04-09 2019-08-07 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
CA2401491C (en) * 2000-03-03 2011-07-05 Kyowa Hakko Kogyo Co., Ltd. Ccr4-binding antibody and diagnostic and therapeutic uses thereof
US6946292B2 (en) * 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
AU2003211550A1 (en) * 2002-02-28 2003-09-09 Kyowa Hakko Kogyo Co., Ltd. Diagnostics and remedies for interstitial pneumonia
AU2003236017B2 (en) 2002-04-09 2009-03-26 Kyowa Kirin Co., Ltd. Drug containing antibody composition
EP1698640B2 (en) 2003-10-01 2019-06-19 Kyowa Hakko Kirin Co., Ltd. Method of stabilizing antibody and stabilized solution-type antibody preparation
CA2542037A1 (en) * 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Composition of antibody capable of specifically binding ccr4
JPWO2005053741A1 (ja) * 2003-12-04 2007-06-28 協和醗酵工業株式会社 ケモカイン受容体ｃｃｒ４に対する遺伝子組換え抗体を含む医薬
US7674459B2 (en) 2003-12-23 2010-03-09 Genentech, Inc. Treatment of cancer with a novel anti-IL13 monoclonal antibody
US20060034841A1 (en) * 2004-06-07 2006-02-16 Kyowa Hakko Kogyo Co., Ltd. Method of depleting regulatory T cell
EP1871807B1 (en) * 2005-02-18 2012-11-28 Dana-Farber Cancer Institute, Inc. Antibodies against cxcr4 and methods of use thereof
US20070172476A1 (en) * 2005-07-28 2007-07-26 Kyowa Hakko Kogyo Co., Ltd. Method of treating B-cell neoplasms or Hodgkin's lymphoma
US20080118978A1 (en) 2006-04-28 2008-05-22 Takashi Sato Anti-tumor agent
GB0718167D0 (en) * 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target
US8962806B2 (en) * 2007-12-28 2015-02-24 Dana-Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
JP5552630B2 (ja) * 2008-10-24 2014-07-16 学校法人 聖マリアンナ医科大学 Ｈｔｌｖ−ｉ関連脊髄症を治療または予防するための医薬、およびｈｔｌｖ−ｉ関連脊髄症の患者に対する抗体療法の効果を試験する方法
GB0909906D0 (en) * 2009-06-09 2009-07-22 Affitech As Antibodies
JP5709061B2 (ja) * 2009-09-10 2015-04-30 協和発酵キリン株式会社 ヒトｃｃケモカイン受容体４（ｃｃｒ４）に特異的に結合する抗体組成物を含む医薬
CN102863533B (zh) * 2010-06-21 2013-12-11 中国科学技术大学 抗体人源化改造方法
JP2013535692A (ja) 2010-08-10 2013-09-12 アムジエン・インコーポレーテツド 標的抗体に対する中和抗体検出用インビトロ二重機能標的結合アッセイ
US10266599B2 (en) 2010-12-07 2019-04-23 Cancer Research Technology Limited Antibodies which bind to the human CC chemokine receptor 4 and uses thereof
GB201020738D0 (en) 2010-12-07 2011-01-19 Affitech Res As Antibodies
MX352789B (es) 2010-12-16 2017-12-08 Genentech Inc Anticuerpo anti-il-13 para usarse en tratar un asma o un trastorno respiratorio.
ES2758884T3 (es) 2011-06-24 2020-05-06 Stephen D Gillies Proteínas de fusión de inmunoglobulina a través de cadena ligera y métodos de uso de ellas
BR112015000068A2 (pt) 2012-07-06 2017-08-08 Kyowa Hakko Kirin Co Ltd método terapêutico e medicamento para mielopatia associada a htlv-1 (ham)
JP6546178B2 (ja) 2013-09-13 2019-07-17 ジェネンテック， インコーポレイテッド 細胞株中の宿主細胞タンパク質及び組換えポリペプチド産物を検出及び定量化するための組成物並びに方法
KR102373930B1 (ko) 2013-09-13 2022-03-11 제넨테크, 인크. 정제된 재조합 폴리펩티드를 포함하는 방법 및 조성물
MX2016015181A (es) 2014-05-21 2017-05-25 Pfizer Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer.
TW201713332A (zh) 2015-07-14 2017-04-16 協和醱酵麒麟有限公司 包含與抗體組合投予之ｉｄｏ抑制物之腫瘤治療劑
EP3471754A1 (en) 2016-06-20 2019-04-24 Kymab Limited Anti-pd-l1 antibodies
SG11202005557TA (en) * 2017-12-12 2020-07-29 Macrogenics Inc Bispecific cd 16-binding molecules and their use in the treatment of disease
CN108250290B (zh) 2018-02-23 2024-03-12 上海捌加壹医药科技有限公司 Ccr4的n端重组蛋白及其用途
CN116731186B (zh) * 2023-07-07 2023-12-26 武汉爱博泰克生物科技有限公司 抗人IgG-Fc兔单克隆抗体及其制备方法、多核苷酸分子、表达载体和宿主细胞

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5608039A (en) * 1990-10-12 1997-03-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Single chain B3 antibody fusion proteins and their uses
US5914110A (en) 1993-09-07 1999-06-22 Smithkline Beecham Corporation Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
JPH0853355A (ja) 1994-08-12 1996-02-27 Taisho Pharmaceut Co Ltd Ｉｌ−５産生抑制剤
GB9501683D0 (en) 1995-01-27 1995-03-15 Glaxo Group Ltd Substances and their uses
US6498015B1 (en) 1995-06-07 2002-12-24 Icos Corporation Methods of identifying agents that modulate the binding between MDC and an MDC receptor
JP3946256B2 (ja) 1995-09-11 2007-07-18 協和醗酵工業株式会社 ヒトインターロイキン５受容体α鎖に対する抗体
IL125658A0 (en) 1997-08-18 1999-04-11 Hoffmann La Roche Ccr-3 receptor antagonists
DE69835441T2 (de) 1997-11-12 2007-08-02 F. Hoffmann-La Roche Ag Behandlung von t-helfer zell typ 2 vermittelten immunkrankheiten mit retinoid antagonisten
US6355244B1 (en) 1997-11-17 2002-03-12 University Of Kentucky Research Foundation Methods and compositions for the treatment of psoriasis
CA2332128A1 (en) 1998-06-26 2000-01-06 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for hypercalcemic crisis
US6245332B1 (en) 1999-01-15 2001-06-12 The Board Of Trustees Of The Leland Stanford Junior University Modulation of systemic memory T cell trafficking
US6488930B1 (en) 1999-01-15 2002-12-03 Millennium Pharmaceuticals, Inc. Anti-CCR4 antibodies and methods of use therefor
EP1050307A1 (en) 1999-05-06 2000-11-08 Applied Research Systems ARS Holding N.V. CCR4 antagonists in sepsis
CA2401491C (en) * 2000-03-03 2011-07-05 Kyowa Hakko Kogyo Co., Ltd. Ccr4-binding antibody and diagnostic and therapeutic uses thereof
JPWO2005053741A1 (ja) * 2003-12-04 2007-06-28 協和醗酵工業株式会社 ケモカイン受容体ｃｃｒ４に対する遺伝子組換え抗体を含む医薬

Also Published As

Publication number Publication date
US20140186349A1 (en) 2014-07-03
WO2003018635A1 (en) 2003-03-06
CY1111193T1 (el) 2015-06-11
US20090227012A1 (en) 2009-09-10
US20180030146A1 (en) 2018-02-01
MXPA04001894A (es) 2005-09-08
AU2002338015B2 (en) 2008-02-07
CA2458627C (en) 2013-09-10
NO20040976L (no) 2004-06-01
KR100959248B1 (ko) 2010-05-26
ES2356190T3 (es) 2011-04-05
JPWO2003018635A1 (ja) 2004-12-09
EP1449850B1 (en) 2010-12-01
US20130273038A1 (en) 2013-10-17
CN100430420C (zh) 2008-11-05
LUC00116I1 (ja) 2019-05-02
US7842797B2 (en) 2010-11-30
EP1449850A1 (en) 2004-08-25
CY2019022I1 (el) 2019-11-27
BRPI0212266B1 (pt) 2020-05-05
EP1449850B9 (en) 2011-05-11
US10131711B2 (en) 2018-11-20
US9051371B2 (en) 2015-06-09
LUC00116I2 (ja) 2019-12-27
AU2002338015B8 (en) 2008-03-20
US20150315285A1 (en) 2015-11-05
PT1449850E (pt) 2011-02-02
NL300985I1 (en) 2019-05-08
BE2019C006I2 (ja) 2021-11-22
BRPI0212266B8 (pt) 2021-05-25
US7504104B2 (en) 2009-03-17
US20110059524A1 (en) 2011-03-10
NO334858B1 (no) 2014-06-23
JP4052515B2 (ja) 2008-02-27
US8143058B2 (en) 2012-03-27
NL300985I2 (en) 2019-11-21
US20030175273A1 (en) 2003-09-18
DK1449850T3 (da) 2011-02-14
FR19C1028I2 (fr) 2021-02-19
DE60238503D1 (de) 2011-01-13
US20120177643A1 (en) 2012-07-12
CA2458627A1 (en) 2003-03-06
KR20040044492A (ko) 2004-05-28
BR0212266A (pt) 2004-10-19
US8900584B2 (en) 2014-12-02
CN1575303A (zh) 2005-02-02
US10590203B2 (en) 2020-03-17
CO5560582A2 (es) 2005-09-30
ATE490277T1 (de) 2010-12-15
CY2019022I2 (el) 2019-11-27
FR19C1028I1 (ja) 2019-05-17
EP1449850A4 (en) 2005-08-10

Similar Documents

Publication Publication Date Title
NL300985I2 (en) mogamulizumab
WO2004050016A3 (en) Delivery of pharmaceutical agents via the human insulin receptor
EP1238985A4 (en) HUMAN ANTIBODY FOR TRANSPLANTATION OF A REGION OF DETERMINATION OF COMPLEMENTARITY AGAINST GANGLIOSIDE GD3, AND DERIVATIVES THEREOF
MXPA03007712A (es) Sales farmaceuticas.
HUP0103484A2 (hu) Anti-CD20-ellenanyag alkalmazása B-sejtes limfómák kombinációs terápiájára
HUP0303952A2 (hu) Terápiás ágens gyermekkori krónikus artrítiszhez hasonló betegségekre
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
TR200001891T2 (tr) ASPB28- İnsan ensülini ve kullanımı.
ATE343969T1 (de) Beschichtete medizinische geräte
TW224428B (ja)
WO2001026693A3 (en) Manufacture of polyglutamate-therapeutic agent conjugates
WO2003009815A3 (en) Compositions and methods for modulating blood-brain barrier transport
EP1702625A4 (en) MEDICAMENT CONTAINING A GENETICALLY MODIFIED ANTIBODY AGAINST THE CHEMOKINE CC R4 RECEPTOR
EP0850648A3 (en) Combination of thrombolytically active proteins and anticoagulants and uses thereof
ES2080037T1 (es) Medicamento de uso topico con actividad cicatrizante.
ATE271852T1 (de) Verbesserte inhalationspräparate
NO985571L (no) Legemiddel for autoimmunsykdommer
WO2000061171A3 (en) Uses of mammalian ox2 protein and related reagents
WO2000063348A3 (fr) Composition pharmaceutique comprenant des cellules nkt activees par des pim, et son utilisation en therapie
TR200202110T2 (tr) "5-[{6-(2-Flüore benzil) oksi-2-naftil}metil]-2,4-tiyazolidin dion kristalleri"
WO1999064065A3 (en) Tumour therapy and imaging
WO2002082077A3 (de) Herstellung polyklonaler, monospezifischer antikörper gegen die upar-varianten del4, del5 und del4+5 sowie deren verwendung für diagnostische und therapeutische zwecke
BR0202759A (pt) Composição farmacêutica de liberação modificada contendo bupropiona como substância ativa
EP0811385A3 (en) Conjugate of a factor specifically recognizing interleukin-2 receptor with ribonuclease
BR0309375A (pt) Tratamento de sìndrome metabólica

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20220826